TOP2A and neoplasm: Next, the synergistic therapeutic effect of cisplatin,[66, 67] a DNA synthesis inhibitor, and doxorubicin,[68, 69] known to inhibit the topoisomerase II (TOP2) pathway, was demonstrated by identifying the ideal ratio and minimum concentrations needed to overwhelm the cellular repair mechanisms in tumor spheroids.